Company Profile

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-29	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI
06-15	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
06-15	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
05-29	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
05-29	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
05-13	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
03-31	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	Aptose Biosciences Inc. - Shareholder/Analyst Call
03-30	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
03-23	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
03-23	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT

03-19	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
03-19	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
11/06/24	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
10/11/23	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
11/08/23	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

07-01	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
06-15	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
06-15	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
05-29	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
05-13	Aptose Biosciences: Q1 Earnings Snapshot	AQ

12-05	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
12-05	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
09/09/23	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
08/09/23	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Manager	Title	Age	Since
C. Payne DFI	Director of Finance/CFO	63	26/06/2022
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	31/10/2019
Rafael Bejar CTO	Chief Tech/Sci/R&D Officer	54	31/12/2019

Aptose Biosciences Inc. Share Price

Stocks

APS

CA03835T4081

Pharmaceuticals

Chart: Aptose Biosciences Inc.

Latest news: Aptose Biosciences Inc.

Last Transcript: Aptose Biosciences Inc.

Analysts' recommendations: Aptose Biosciences Inc.

Press Releases: Aptose Biosciences Inc.

News in other languages: Aptose Biosciences Inc.

Managers and Directors: Aptose Biosciences Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/06/26	C. Payne	Issuer sale	Chief Financial Officer	-1,255,244	49.1784%
30/06/26	Denis Burger	Issuer sale	Director	-528,737	20.7151%
30/06/26	William Rice	Issuer sale	Chief Executive Officer	-6,026,252	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES INC.	-.--%	+9.09%	-	-	4.32M
ELI LILLY AND COMPANY	-2.54%	+1.31%	+54.27%	+117.14%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+38.56%	+74.05%	635B
ABBVIE INC.	+0.16%	+0.08%	+25.29%	+96.64%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+44.14%	+64.55%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.04%	+40.18%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.98%	+49.15%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.33%	+21.60%	266B
AMGEN INC.	-1.79%	+1.57%	+50.56%	+61.40%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.02%	+99.06%	193B
Average	-0.98%	+1.60%	+37.02%	+69.31%	444.85B
Weighted average by Cap.	-1.35%	+1.63%	+41.02%	+80.33%